TNGX · Tango Therapeutics, Inc.

Tango Therapeutics’ Q1 2026 financial results reflect a strategic pivot toward late-stage development of vopimetostat, evidenced by a $2.9 million year-over-year decline in R&D expenses driven primarily by discontinuation of the TNG908 program and reduced costs for TNG961 and discovery activities — partially offset by increased investment in vopimetostat and TNG456 clinical advancement. The $3.7 million increase in G&A expenses reflects higher personnel-related costs, including share-based compensation, consistent with recent executive appointments (CFO Matthew Gall, CDO Yen-Ching Chua, SVP Strategy Janice Kapty). Collaboration revenue dropped to zero after full recognition of Gilead-related deferred revenue in 2025 following termination of research activities, eliminating a prior revenue stream and reinforcing reliance on internal pipeline progress. With $379.8 million in cash and equivalents as of March 31, 2026, Tango maintains a projected runway into 2028 — explicitly tied to anticipated clinical inflection points, including 2026 data readouts from vopimetostat combinations (daraxonrasib/zoldonrasib), monotherapy lung cancer, and TNG456 in glioblastoma. The board reshuffle — removing two long-standing directors and appointing Sung Lee to lead both the Compensation and NCG Committees — signals governance realignment ahead of potential pivotal trial initiation in MTAP-deleted pancreatic cancer. Management commentary underscores confidence in vopimetostat’s registrational path, contingent on forthcoming combination data, while acknowledging execution risks inherent in clinical trial enrollment, regulatory engagement, and capital requirements beyond 2028.